Spots Global Cancer Trial Database for tagrisso
Every month we try and update this database with for tagrisso cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | NCT03485326 | Non-small Cell ... | - | AstraZeneca | ||
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | NCT05120349 | Non-Small Cell ... | Osimertinib Placebo | 18 Years - | AstraZeneca | |
| Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | NCT02736513 | Lung Cancer | AZD9291 | 18 Years - | Soroka University Medical Center | |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | NCT04486833 | Carcinoma, Non-... | quaratusugene o... osimertinib Platinum-Based ... | 18 Years - | Genprex, Inc. | |
| A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases | NCT05033691 | NSCLC EGFR Gene Mutat... EGF-R Positive ... Non-small Cell ... Brain Metastase... | Stereotactic su... | 18 Years - 120 Years | Hadassah Medical Organization | |
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | NCT05120349 | Non-Small Cell ... | Osimertinib Placebo | 18 Years - | AstraZeneca | |
| Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | NCT02736513 | Lung Cancer | AZD9291 | 18 Years - | Soroka University Medical Center | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | NCT03485326 | Non-small Cell ... | - | AstraZeneca | ||
| A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC | NCT04606771 | Non-Small Cell ... | Osimertinib + S... Savolitinib + P... | 18 Years - | AstraZeneca | |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | NCT04486833 | Carcinoma, Non-... | quaratusugene o... osimertinib Platinum-Based ... | 18 Years - | Genprex, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
